Home › Companies › ATAI

AtaiBeckley Inc.

ATAI Lead: Phase 3 8 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2026-03-06

Pipeline (5 active programs)

mebufotenin

mebufotenin benzoate · BPL-003

Small Molecule Target: 5-HT1A, 5-HT2A

Treatment-Resistant Depression Phase 3 nasal

dimethyltryptamine

VLS-01

Small Molecule Target: 5-HT1, 5-HT2, 5-HT6, 5-HT7

Treatment-Resistant Depression Phase 2 oral

R-MDMA

EMP-01

Small Molecule Target: 5-HT2A

Social Anxiety Disorder Phase 2 oral

EGX-A

EGX-B

Small Molecule Target: 5-HT2A, 5-HT2C

Treatment-Resistant Depression Preclinical
Opioid Use Disorder Preclinical National Institute on Drug Abuse

Biotech Distilled coverage (8)

2026-05-12 UPDATE: AtaiBeckley (ATAI) - The Phase 3 Blueprint, Decoded 🔒 Paid
2026-04-27 UPDATE: AtaiBeckley (ATAI) - Two Data Drops, One 38% Rally, and the Phase 3 Clock Ticking 🔒 Paid
2026-03-29 UPDATE: Atai Beckley (ATAI) - The Index Effect Takes Hold Ahead of Q2
2026-03-22 UPDATE: Atai Beckley (ATAI) - BPL-003 Gets Peer-Reviewed Validation as Phase 3 Approaches 🔒 Paid
2026-03-07 UPDATE: Atai Beckley (ATAI) - FDA Greenlights BPL-003 Phase 3; 10-K Confirms 2029 Runway 🔒 Paid
2026-02-28 UPDATE: Atai Beckley (ATAI) - EMP-01 Delivers a Phase 2a Win, But the Market Yawns 🔒 Paid
2026-01-11 UPDATE Atai Beckley (ATAI): JPM Update, Phase 3 Timelines, and Cash Runway to 2029 🔒 Paid
2025-12-24 Atai Beckley (ATAI): Scientific Due Diligence for Lead and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.